NCT01228435View on ClinicalTrials.gov

IPI-504 in NSCLC Patients With ALK Translocations

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Lung CancerStage IIIb Lung CancerStage IV Lung Cancer
Interventions
DRUG

IPI-504

Given intravenously twice weekly for 2 weeks followed by 10 day off treatment

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Infinity Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT01228435 - IPI-504 in NSCLC Patients With ALK Translocations | Biotech Hunter | Biotech Hunter